(VIANEWS) - RPC (RES), Regions Financial Corporation (RF), Incyte Corporation (INCY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RPC (RES)
46.1% sales growth and 20.47% return on equity
Through its subsidiaries, RPC, Inc. provides an array of equipment and services for oil and natural gas companies that are involved in exploration, production, or development of oil-and gas properties. Technical Services and Support Services are the two main segments of RPC, Inc. Technical Services provides services such as pressure pumping and fracturing. Support Services provides rental tools such as blowout preventors. high pressure manifolds. valves. Hevi-wate drillpipes. Tubing products. Production related tools. Pumps, diverters. Drill pipes. drill collars. handling tools. Wear Knot drillpipes are for offshore and onshore oil and gas well drilling. The segment offers services such as oilfield inspections, pipe management and storage; oilfield consulting and training services. The company operates internationally in America, Africa, Canada and China. RPC, Inc. was established in 1984. It is located in Atlanta, Georgia.
Earnings Per Share
As for profitability, RPC has a trailing twelve months EPS of $0.64.
PE Ratio
RPC has a trailing twelve months price to earnings ratio of 12.38. Meaning, the purchaser of the share is investing $12.38 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.47%.Earnings before Interest, Taxes and Depreciation
RPC's EBITDA stands at 1.26.
Volume
Today's last reported volume for RPC is 1038000 which is 11.01% below its average volume of 1166530.
Growth Estimates Quarters
The company's growth estimates for the current quarter and the next is 383.3% and 271.4%, respectively.2. Regions Financial Corporation (RF)
18.8% sales growth and 11.82% return on equity
Regions Financial Corporation is a financial holding firm that provides bank and other related services for individual and corporate clients. The company operates in three segments, namely Corporate Bank and Consumer Bank. The Corporate Bank segment provides commercial banking services such as investment real estate and commercial realety lending, equipment leasing financing, deposit products, securities placement and placement, loan syndicatation and placement, foreign currency, derivatives and merger and acquisition. This bank serves investors, developers, commercial realty, middle-market, corporate and other types of real estate. Consumer Bank offers a range of consumer banking services, including residential mortgages, home equity loans and lines, credit cards for consumers, and deposits. Wealth Management offers credit-related products and retirement and savings options; trust and investment management, assets management and estate planning services for individuals, businesses and governmental institutions. It also offers investment and insurance products, low-income housing tax credit corporate funds syndication and other special financing services. It operated through 1,300 banks offices across Texas, the Midwest and South. Regions Financial Corporation was established in 1971. Its headquarters are located in Birmingham, Alabama.
Earnings Per Share
As for profitability, Regions Financial Corporation has a trailing twelve months EPS of $1.52.
PE Ratio
Regions Financial Corporation has a trailing twelve months price to earnings ratio of 13.55. Meaning, the purchaser of the share is investing $13.55 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.82%.Annual Top and Bottom Value
Regions Financial Corporation stock was valued at $20.61 as of 19:22 EST. This is way below its 52 week high of $25.57, and way higher than its 52 week low of $18.01.
Growth Estimates Quarters
The company's growth estimates for the current quarter and the next is 48.8% and 14.5%, respectively.Revenue growth
The year-on-year revenue growth fell by 2% and now stands at 6.58 billion for the 12 trailing months.
Sales Growth
Regions Financial Corporation's sales growth is 17.1% for the current quarter and 18.8% for the next.
3. Incyte Corporation (INCY)
12.7% sales growth and 26.92% return on equity
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $-1.36.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.92%.Sales Growth
Incyte Corporation's sales growth is 1.7% for the ongoing quarter and 12.7% for the next.
Moving Average
Incyte Corporation is worth more than its $50-day average value of $76.39, and greater than its $200-day average value of $75.20.Volume
Incyte Corporation's latest reported volume is 670354, which is 53.35% less than its average volume 1437080.
Revenue growth
The year-over-year growth in quarterly revenue was 29.1%. We now have 3.32B dollars for the 12 trailing months.
4. NXP Semiconductors (NXPI)
12.7% sales growth and 33.37% return on equity
NXP Semiconductors N.V. provides a variety of semiconductor products. NXP Semiconductors N.V. offers a variety of semiconductor products. Products from the company are utilized in many applications including mobile, automotive, industrial, Internet of Things and communications infrastructure. It sells its products to contract and original equipment manufacturers as well as distributors. The company operates internationally in China, Japan, South Korea and South Korea. The company used to be known as KASLION acquisition B.V., but changed its name in May 2010 to NXP Semiconductors N.V. NXP Semiconductors N.V. is an organization that was founded in 2006. Its headquarters are in Eindhoven in the Netherlands.
Earnings per Share
NXP Semiconductors' trailing twelve-month EPS is $1.5.
PE Ratio
NXP Semiconductors' trailing 12-month price-earnings ratio is 106.8. The purchaser of the shares is therefore investing $106.8 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 33.37%.Moving Average
NXP Semiconductors's value is higher than its 50-day moving average of $158.80 and under its 200-day moving average of $168.77.Volume
The current reported NXP Semiconductors volume is 1028650, which is 55.22% lower than its average volume (229765)
Growth Estimates Quarters
For the current quarter, the company expects to grow by 27.8% and 11.9% respectively.Yearly Top and Bottom Value
NXP Semiconductors's stock is valued at $160.41 at 19:22 EST, way under its 52-week high of $234.90 and way above its 52-week low of $132.08.